Novo Nordisk A/S (NVO) Q1 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Novo Nordisk A/s Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.156 Good day and thank you for standing by. Welcome to the Q1 2026 Novo Nordisk 00:00:05.156 -- 00:00:10.181 earnings conference call. At this time, all participants are in a listen only mode. 00:00:10.181 -- 00:00:13.464 After the speaker's presentation, there'll be a question and answer session. 00:00:13.464 -- 00:00:17.948 To ask a question during the session, you will need to press star one and one on your 00:00:17.948 -- 00:00:22.692 telephone. You will then hear an automated message advising your hand is raised. 00:00:22.692 -- 00:00:26.196 To withdraw your question, please press star one and one again. 00:00:26.196 -- 00:00:30.052 Please be advised that today's conference is being recorded. 00:00:30.052 -- 00:00:34.016 I would now like to hand the conference over to your first speaker today, Michael Novot, 00:00:34.016 -- 00:00:38.038 Head of Investor Relations. Please go ahead. 00:00:38.340 -- 00:00:40.342 Thank you very much, operator. 00:00:40.342 -- 00:00:45.625 Welcome to this Novo Nordisk earnings call for the first three months of 2026. 00:00:45.687 -- 00:00:49.930 My name is Michael Novot. I'm the Head of Investor Relations at Novo Nordisk. 00:00:49.930 -- 00:00:54.635 With me today, I have CEO of Novo Nordisk, Mike Duster, 00:00:54.635 -- 00:00:59.692 EVP US Operations, Jamie Millar, EVP International Operations, 00:00:59.692 -- 00:01:04.898 Emil Kongshuy Larsen, EVP Research and Development and Chief Scientific Officer, 00:01:04.898 -- 00:01:10.344 Martin Holtz-Lange, and Chief Financial Officer, Carsten Munch Knudsen. 00:01:10.344 -- 00:01:13.287 All speakers will be available for the Q&A session. 00:01:13.287 -- 00:01:18.292 Today's call is being webcasted live, and a recording will be made available at our website. ...